Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Precision Biosciences, Inc.

Clinical trials sponsored by Precision Biosciences, Inc., explained in plain language.

Precision BioSciences, Inc. DTIL NASDAQ

A clinical-stage biotech developing gene editing therapies.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 2 Not yet finished but already full! 1

Gene editing for hepatitis b: researchers track Long-Term safety

Disease control ENROLLING_BY_INVITATION

This study monitors 45 people with chronic hepatitis B who already received the experimental gene editing treatment PBGENE-HBV in an earlier trial. Researchers will watch for any delayed side effects over time. No new treatment is given; the goal is to understand the long-term sa…

Sponsor: Precision BioSciences, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:23 UTC